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Tumescent lidocaine anesthesia (TLA) was developed for performing liposuction totally by local anesthe-sia with virtually no surgical blood loss.1,2 TLA has 
been extended to a wide range of other surgical procedures 
involving cutaneous, subcutaneous, breast, and vascular 
tissues.3–25 The maximum safe dosage of tumescent lido-
caine for these procedures is unknown. There is a need for a 
pharmacokinetic-based estimate of the maximum safe mil-
ligram per kilogram dosage of tumescent lidocaine.26,27
The package insert labeling approved by the United 
States Food and Drug Administration (FDA) for lidocaine 
with epinephrine states that the recommended maximal 
dosage is 7 mg/kg for infiltration local anesthesia. The 
FDA has no data to support this 7 mg/kg as the dosage 
limit, which was established in 1948 for epidural anesthe-
sia. The liposuction guidelines of the American Society for 
Dermatologic Surgery recommended that the maximal safe 
milligram per kilogram dosage of tumescent lidocaine for 
liposuction totally by local anesthesia is 55 mg/kg.28
Tumescent lidocaine solution contains at most 1 g lido-
caine and 1 mg epinephrine in 100 mL plus 10 mEq sodium 
bicarbonate in 10 mL added to 1000 mL of 0.9% physiologic 
saline for a final lidocaine concentration of 1 g per bag con-
taining 1110 mL or 0.9 g/L (0.09%). Sodium bicarbonate 
reduces the stinging discomfort of large volume subcutane-
ous tumescent infiltration.29
Subcutaneous infiltration of large volumes of TLA 
solution causes the targeted tissue to become temporar-
ily swollen and firm or tumescent. The resulting increased 
subcutaneous interstitial pressure spreads the TLA solu-
tion through adjacent tissues by bulk flow. Lidocaine tox-
icity is a function of serum lidocaine concentration. Dilute 
epinephrine produces intense local vasoconstriction, slows 
systemic absorption of lidocaine, and thus reduces peak 
serum lidocaine concentrations, which reduces the risk of 
systemic lidocaine toxicity. The removal of a significant vol-
ume of tumescent subcutaneous fat by liposuction removes 
a significant portion of the tumescent lidocaine before it is 
absorbed into the systemic circulation. The threshold serum 
concentration for mild lidocaine toxicity (lightheadedness, 
paresthesias, tinnitus, blurred vision, nystagmus, ataxia, 
slurred speech, confusion) is 6 μg/mL.30–32
The principal aim of our research was to measure serum 
lidocaine concentrations as a function of milligram per kilo-
gram dosage of tumescent lidocaine. Our main hypothesis 
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was that dosages of tumescent lidocaine that are consider-
ably larger than 7 mg/kg are a nonsignificant risk of harm 
to patients.
The research had 4 specific aims. The first specific aim 
was to measure sequential serum lidocaine concentrations 
over 24 hours for each subject after subcutaneous infiltration 
of TLA on 3 separate occasions where the initial infiltrations 
were followed by no liposuction and the last infiltration 
was followed by liposuction. It has been suggested that IV 
lidocaine may have beneficial perioperative effects.33–37 We 
hypothesized that tumescent infiltration without liposuc-
tion produces a serum lidocaine concentration-time profile 
resembling a constant IV infusion lasting 12 to 16 hours 
or more. Furthermore, we hypothesized that liposuction 
removes significant amounts of lidocaine before it can be 
systemically absorbed. If the later hypothesis is true, then 
lidocaine data derived from liposuction patients cannot be 
used to establish the maximum recommended milligram 
per kilogram dosage of tumescent lidocaine for surgical 
procedures that do not involve liposuction.
The second aim was to record heart rate associated with 
doses of tumescent epinephrine and document adverse 
signs or symptoms associated with serum lidocaine concen-
trations. We hypothesized that tachycardia is uncommon 
and that adverse events associated with the large dosages 
of tumescent lidocaine and epinephrine are uncommon.
The third aim was to analyze the association between the 
milligram per kilogram dosage of tumescent lidocaine and 
subsequent peak serum lidocaine concentrations (Cmax) 
both without and with liposuction. We hypothesized that 
there is a linear relationship between the milligram per kilo-
gram dosage of tumescent lidocaine and Cmax. Such a linear 
relationship would allow one to estimate Cmax as a function 
of milligram per kilogram dosage of tumescent lidocaine.
The fourth aim was to use tolerance interval analysis to 
calculate the proportion of individuals who, when given a 
specified milligram per kilogram dosage of tumescent lido-
caine, will have a Cmax exceeding 6 μg/mL. We hypoth-
esized that there are dosages larger than 7 mg/kg that are 
associated with a risk of mild lidocaine toxicity (Cmax 
≥ 6 μg/mL) of <1/1000 and therefore are a nonsignificant 
risk of harm to patients.
METHODS
This research was supported by the authors and registered at 
clinicaltrials.gov: NCT00977028. Before every procedure, sub-
jects signed written informed consent approved by an IRB.
Inclusion criteria were ASA physical status I or II, no 
use of drugs that inhibit platelet function or inhibit the 
hepatic microsomal enzymes cytochrome P450 (CYP1A2 or 
CYP3A4) responsible for lidocaine metabolism, no clinical 
evidence of infection, and a negative urine pregnancy test. 
Prospective subjects had to first request liposuction before 
being informed of the opportunity to participate in this 
research. Participants were offered liposuction at no charge.
Individual subjects served as their own controls. Large 
volume (≥500 mL) tumescent infiltration was accomplished 
using a peristaltic tumescent infiltration pump (HKSurgical.
com, San Clemente, CA). Subcutaneous tumescent infiltra-
tion was initiated by briefly using a spinal needle (20 gauge 
× 8.5 cm) to infiltrate a relatively small volume of tumescent 
lidocaine solution sufficient to allow subsequent painless 
insertion of blunt-tipped (16 gauge × 15 cm) multiorifice 
tumescent infiltration cannulas.
The anatomic area targeted for infiltration was constant 
for each subject. These areas, which varied among subjects, 
included abdomen, outer thigh, hips, back, inner thighs 
and knees, and female breasts. To minimize the chrono-
tropic effects of epinephrine, most patients received oral 
clonidine 0.1 mg before tumescent infiltration. Clonidine 
(0.1 mg) and/or lorazepam (1 mg) by mouth 15 minutes 
before infiltration counteracted the tachycardia associated 
with epinephrine and provided mild anxiolysis and seda-
tion. No narcotic analgesia or parenteral sedation was used. 
Prophylactic atropine, 0.3 mg IV or IM was administered to 
subjects with a history of syncope or near-syncope.
Each tumescent lidocaine infiltration procedure was fol-
lowed by sequential serum lidocaine samples and clinical 
status evaluations at times T = 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 
and 24 hours beginning immediately upon completion of 
infiltration.
For the 24 hours after infiltration, whenever serum 
samples were obtained, the awake patients were evaluated 
for any unpleasant subjective symptoms or signs of mild 
toxicity, including: lightheadedness, perioral numbness or 
nausea, tinnitus, blurred vision, nystagmus, ataxia, slurred 
speech, or confusion.
Patient monitoring during the first 12 to 14 hours included 
continuous cardiac rhythm, heart rate, pulse oximetry, and 
automatic arterial blood pressure. Heart rates, before, dur-
ing, and after tumescent infiltration and immediately after 
liposuction were compared.
Serum samples were obtained from a peripheral vein 
using an indwelling 20-gauge IV catheter by a 2-syringe 
sampling technique. The first syringe contained 2 mL 
saline to flush the IV catheter and then remove and discard 
2 mL of blood. Next, 10 mL blood was collected in a second 
syringe for assay of lidocaine by high-performance liquid 
chromatography by NMS Labs, Willow Grove, PA.38 The 
catheter was then flushed with 1 mL heparin 10 USP units 
per milliliter.
For each subject, the initial infiltration procedures were 
done without subsequent liposuction, and the final tumes-
cent infiltration was followed by liposuction after allowing 
at least 1 hour of detumescence for gradual dispersion of 
subcutaneous tumescent fluid. Tumescent infiltration pro-
cedures were separated by at least 1 week. The liposuction 
aspirate was collected in clear plastic volumetric canisters. 
After allowing at least 1 hour for gravitational separation 
of the lipid and aqueous aspirate, the resulting supernatant 
fat, infranatant blood-tinged tumescent anesthetic solution, 
and the total aspirate volume were recorded.
Serum lidocaine concentrations as a function of time, 
Cmax, the time when Cmax occurred (Tmax), and Cmax 
as a function of milligram per kilogram dosage of lidocaine 
were determined. Area under the curve (AUC∞) of serum 
lidocaine concentration-time profile was calculated by the 
trapezoid method. AUC∞, Cmax, and Tmax without and 
with liposuction were compared by the paired t test.
In some individual subjects, the lidocaine concentra-
tion (mg/L) in the TLA solutions and the lidocaine dosage 
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(mg/kg) varied between procedures to achieve a targeted 
milligram per kilogram dosage of lidocaine and to have suf-
ficient volume of TLA solution to accomplish liposuction of 
the area.
The choices of the milligram per kilogram dosages used 
in the present research were motivated by clinical experi-
ence with tumescent liposuction totally by local anesthe-
sia. Worldwide experience with tumescent liposuction has 
shown that 45 mg/kg with liposuction is quite safe. Without 
liposuction, the range of safe dosages is not known.
The Cmax following 35 mg/kg without liposuction in 
the first 2 subjects was well below the toxic threshold of 
6 μg/mL. These results provided pharmacokinetic assur-
ance that 45 mg/kg without liposuction would not repre-
sent a significant risk of harm to the subjects.
To achieve an adequate range of input data for linear 
regression analysis, some of the subjects who received 
45 mg/kg without liposuction also received 22.5 mg/kg 
(half of 45 mg/kg) in the second study without liposuction.
Statistical Analysis
We analyzed the data. The effect of liposuction on the sys-
temic bioavailability of subcutaneous tumescent lidocaine 
was assessed by pairwise comparison of AUC∞s (paired 
t test) among subjects whose individual dosages of tumes-
cent lidocaine were the same without and with liposuction.
To assure statistical independence of these observa-
tions when comparing AUC∞ without and with liposuc-
tion, if a subject had 2 tumescent infiltration procedures 
without liposuction, then only 1 AUC∞ measurement was 
used in the paired t test. When these 2 lidocaine doses 
without liposuction were not equal, then we chose the 
dose that was the same as the dose with liposuction. If a 
subject’s 2 tumescent lidocaine doses without liposuction 
both equaled the dosage with liposuction, then we chose 
the smaller AUC∞ without liposuction. Because liposuc-
tion removes lidocaine before it can be absorbed systemi-
cally, the AUC∞ without liposuction is likely to be larger 
than the AUC∞ with liposuction. The choice of the smaller 
AUC∞ without liposuction was conservative, in the sense 
that it reduced the likelihood that the paired t test com-
paring AUC∞ without and with liposuction would incor-
rectly detect a significant difference between a subject’s 
AUC∞s (type I error).
For linear regression analysis of Cmax as a function 
of milligram per kilogram lidocaine dosage, only 1 of the 
2 dosages without liposuction was used to assure statistical 
independence of observations. When the milligram per kilo-
gram doses of lidocaine without liposuction were not equal, 
then the smallest of the 2 doses of lidocaine was used in 
the linear regression analysis to maximize the range of milli-
gram per kilogram doses. When the milligram per kilogram 
doses of lidocaine without liposuction were equal, then the 
largest of the 2 Cmax values was chosen. The choice of the 
larger Cmax is conservative, in the sense that it increased 
the estimated probability that any given milligram per kilo-
gram dose would produce a Cmax ≥6 μg/mL.
We used tolerance interval analysis to estimate the 
probability that a future milligram per kilogram dosage of 
tumescent lidocaine given to an individual would result in 
a Cmax ≥6 μg/mL.39–41 Tolerance intervals were calculated 
at a 99% level of confidence.
Supplemental Digital Content 1 (http://links.lww.com/
AA/B335) contains safety tips, and information regarding 
clinical lidocaine toxicity, case reports of tumescent lido-
caine toxicity, tumescent lidocaine pharmacokinetics, for-
mulation of TLA solution, tumescent infiltration techniques, 
detumescence, technique for calculating AUC∞, tolerance 
intervals, and R-Code to compute tolerance intervals.
Supplemental Digital Content 2 (http://links.lww.com/
AA/B336) is a video of the technique for painless subcuta-
neous infiltration of large volumes of tumescent lidocaine.
RESULTS
There were 41 TLA infiltration procedures. With 1 exception, 
all subjects had at least 2 tumescent infiltration procedures 
without subsequent liposuction and then 1 infiltration fol-
lowed by liposuction. A single subject participated in only 
1 TLA infiltration procedure without liposuction. All but 1 
subject received the same milligram per kilogram dose of 
lidocaine at least once without liposuction and once with 
liposuction. The lidocaine concentration-time profile for 
each of the 14 subjects is shown in Figure 1. No subject expe-
rienced a peak serum lidocaine concentration larger than 
4.4 μg/mL. Tables  1 and 2 present lidocaine dosage data, 
without and with liposuction, respectively.
Without liposuction, the range of lidocaine content in 
bags of tumescent solution was 700 to 1000 mg/bag. With 
liposuction, the range of lidocaine content was 770 to 
1000 mg/bag. The ranges of milligram per kilogram dosages 
of lidocaine were 19.2 to 45.0 mg/kg without liposuction 
and 19.4 to 52 mg/kg with liposuction. Ten subjects received 
45 mg/kg without liposuction and at least 45 mg/kg with 
liposuction. The total milligram dose of tumescent lidocaine 
ranged from 1800mg to 3600mg. During this research, the 
volume of infiltrated TLA solution ranged from 2 to 4 L. 
Subjects received no IV fluids, no systemic sedatives, and no 
narcotic analgesics.
Among those who received 45 mg/kg tumescent lido-
caine for liposuction, the mean total volume of aspirate was 
2416 mL (range, 1525–3300 mL), mean volume of super-
natant fat was 1863 mL (range, 1250–2900 mL), and mean 
volume infranatant blood-tinged anesthetic solution was 
553 mL (range, 130–1100 mL).
At equal milligram per kilogram dosages of tumescent 
lidocaine without and with liposuction, the mean AUC∞ 
for serum lidocaine concentration-time profile without lipo-
suction (56.2 μg·h/mL) was significantly higher than that 
with liposuction (40.7 μg·h/mL; P = 0.001). As presented in 
Figure 2, liposuction removed approximately 28% of the lido-
caine before it could be absorbed into the systemic circulation.
At equal milligram per kilogram dosages of tumescent lido-
caine, the mean Cmax without liposuction 2.9 μg/mL (range, 
1.2–4.4) was significantly higher than the mean Cmax with 
liposuction 2.38 μg/mL (range, 0.97–3.8) by the paired t test 
(P = 0.001). The mean Tmax without liposuction was 13.1 hours 
(range, 8–24), which was not significantly different from the 
mean Tmax with liposuction 12.5 hours (range, 8–18; P = 0.19).
Without liposuction, the dose of epinephrine ranged 
from 1.2 to 4.3 mg and the mean difference in heart rate 
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before and after infiltration was −3.4 (range, −24 to +17). 
With liposuction, the dose of epinephrine ranged from 1.6 
to 4.3 mg, and the difference in heart rate before infiltra-
tion and after liposuction was not significant (P = 0.13; 
mean = +5; range, −12 to +33).
One subject who was relatively thin, with body mass 
index of 20, received 45 mg/kg without liposuction, which 
produced a Cmax of 4.3 μg/mL and experienced transient 
nausea approximately 12 hours after infiltration. There were 
no other lidocaine-associated adverse events.
Figure 1. (Continued )
Tumescent Lidocaine Anesthesia
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There was no clinical evidence of epinephrine toxic-
ity, such as chest pain or discomfort, dyspnea, dizziness, 
headache, anxiety, nervousness, restlessness, tremors, dia-
phoresis, pallor, rapid, irregular or pounding heart rate, or 
pounding in the ears.
There were no observed signs or symptoms of neurotox-
icity, syncope, and near-syncope. There was no evidence of 
cardiac toxicity, such as arrhythmia, tachycardia, bradycar-
dia, hypertension, hypotension, volume overload heart fail-
ure, pulmonary edema, or hypoxia.
Without liposuction, there was a strong linear relation-
ship between milligram per kilogram dosage of tumescent 
lidocaine and Cmax (R2 = 0.85; Fig.  3). With liposuction, 
there was a weaker linear relationship between milligram 
per kilogram dosage of tumescent lidocaine and Cmax 
(R2 = 0.36; see Fig. 4).
Based on the tolerance interval analysis, the estimated 
probability that a future milligram per kilogram dose of 
tumescent lidocaine given to an individual would result in 
a Cmax ≥6 μg/mL is shown in Table 3.
Supplemental Digital Content 3 (http://links.lww.com/
AA/B337) presents patient-level raw data and additional anal-
ysis including tables in comma-separated values (cvs) format.
DISCUSSION
Our findings confirmed our main hypothesis that doses of 
TLA that are far larger than the current FDA limit of 7 mg/kg 
are a nonsignificant risk of harm to patients.
After the subcutaneous infiltration of tumescent lido-
caine, we observed the serum concentration-time profiles 
without and with liposuction and found that tumescent 
lidocaine absorption continues beyond 24 hours. For a 
given dosage of a drug, prolonging its systemic absorption 
reduces its Cmax. This explains the remarkable safety of 
large dosages of tumescent lidocaine and epinephrine.
At equal doses of tumescent lidocaine, the average AUC∞ of 
the concentration-time profiles is 28% smaller with liposuction 
than it is without liposuction. This supports our hypothesis 
that liposuction removes a significant amount of subcutane-
ous tumescent lidocaine before it can be absorbed into the cir-
culation. Thus, data derived from liposuction patients cannot 
be used to estimate the maximal safe milligram per kilogram 
dosage of tumescent lidocaine without liposuction.
Furthermore, these concentration-time profiles resemble 
the profile of a constant IV lidocaine infusion that is discon-
tinued at Tmax. There is a growing literature indicating that 
systemic IV lidocaine may have beneficial perioperative 
effects, including preemptive analgesia, reduced postopera-
tive narcotic requirements, and reduced systemic inflam-
matory response to surgical trauma.33,34,42–47 The observation 
that tumescent infiltration produces a concentration-time 
profile similar to a constant IV infusion of lidocaine sug-
gests a new hypothesis, to be tested in the future, that local 
TLA may have desirable systemic effects.
During each of the 41 studies, we observed heart rate, 
arterial blood pressure, pulse oximetry, and cardiac rhythm 
and inquired about any subjective symptoms suggestive 
of lidocaine toxicity. There were no episodes of tachy-
cardia although most patients did receive oral clonidine 
(0.1 mg) for its anxiolytic effect and to counteract the positive 
chronotropic effects of epinephrine. One patient encoun-
tered a brief episode of nausea at 45mg/kg without liposuc-
tion. The data indicates that without liposuction 45mg/kg 
is risky, while 28mg/kg is a more reasonable maximal safe 
dosage. Otherwise, careful observation of patients over the 
course of 41 pharmacokinetic studies revealed no adverse 
events associated with the systemic effects of lidocaine and 
epinephrine. This finding confirmed our hypothesis that 
adverse events associated with the large dosages of tumes-
cent lidocaine with epinephrine are infrequent.
Figure 1. Serum lidocaine concentrations over time for each of the 14 subjects after subcutaneous infiltration of tumescent lidocaine anes-
thesia. Subject number and anatomic area of infiltration are presented on the top of each plot. The figure legend presents whether or not 
liposuction was done after tumescent infiltration indicated by “No Lipo” and “Lipo,” respectively, and the tumescent lidocaine dosage (mg/kg).
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The association between the milligram per kilogram dos-
age of tumescent lidocaine and the subsequent peak serum 
lidocaine concentrations (Cmax) was analyzed both without 
and with liposuction. The data confirmed our hypothesis 
that there is a close linear relationship between the milli-
gram per kilogram dosage of tumescent lidocaine without 
liposuction and Cmax. Thus, an increased milligram per 
kilogram dosage of tumescent lidocaine is associated with 
an increased risk of toxicity.T
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Figure 2. Comparison of serum lidocaine concentrations at sequen-
tial times over 24 h following 45 mg/kg tumescent lidocaine, without 
liposuction (closed circles) and with liposuction (open circles). The 
AUC∞ of the mean concentrations (solid line) at each time point with-
out liposuction (56.2 μg·h/mL) is 28% greater than the AUC∞ of the 
mean concentrations (dashed line) with liposuction (40.7 μg·h/mL).
Figure 3. Scatter plot of tumescent lidocaine dosage versus peak 
serum lidocaine concentrations (Cmax) without liposuction. The 
solid line represents the line of regression with a coefficient of deter-
mination (R2) of 0.85.
Figure 4. Scatter plot of tumescent lidocaine dosage versus peak 
serum lidocaine concentrations (Cmax) with liposuction. The solid 
line represents the line of regression with a coefficient of determina-
tion (R2) of 0.35.
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Liposuction removes lidocaine before it can be absorbed 
and thus reduces the correlation between the milligram 
per kilogram dosage of tumescent lidocaine liposuction 
and Cmax. With liposuction, an estimate of the maximum 
safe dosage of tumescent lidocaine is less reliable than 
without liposuction. Years of worldwide experience have 
shown that 55 mg/kg tumescent lidocaine for liposuction 
is remarkably safe.48,49 This dosage is safe most of the time. 
Multiple large surveys involving thousands of procedures 
have found no evidence of tumescent lidocaine toxicity 
at recommended dosages.50–52 However, 55 mg/kg may 
be too risky if lidocaine absorption is too rapid (failure 
to add epinephrine to the solution of tumescent lido-
caine) or if lidocaine metabolism is too slow (diabetes,53 
adverse interactions with drugs that inhibit the hepatic 
microsomal isoenzymes cytochrome P450 3A4 and 1A2 
such as erythromycin,54 sertraline, fluconazole or cipro-
floxacin, propofol,55 or general anesthesia56) or if patients 
have very low serum protein concentrations or if surgery 
is cancelled before liposuction can be completed. Based 
on the present data and considerable worldwide expe-
rience, we believe that 45 mg/kg is a safe and prudent 
maximum dosage of tumescent lidocaine for liposuction. 
Furthermore, 45 mg/kg is less likely than 55 mg/kg to 
permit excessive amounts of liposuction.
Tolerance interval analysis was used to calculate the 
proportion of individuals who, when given a specified 
milligram per kilogram dosage of tumescent lidocaine, 
will have a Cmax exceeding 6 μg/mL. The results con-
firmed our hypothesis that dosages larger than 7 mg/kg 
are associated with a risk of <1/1000 for mild lidocaine 
toxicity. In particular, without liposuction, a dosage of 
45 mg/kg has an estimated risk of mild toxicity of 1/80 
and at 28 mg/kg the estimated risk of mild toxicity was 
several orders of magnitude <1/2000. With liposuction, 
a dosage of 45 mg/kg has an estimated risk of mild toxic-
ity of 1/2000. Thus, the risk of mild toxicity at 28 mg/kg 
without liposuction and 45 mg/kg with liposuction is 
each <1/1000 and can be said to represent a nonsignifi-
cant risk of harm to patients. For nonliposuction surger-
ies, 28 mg/kg tumescent lidocaine is a prudent choice 
while allowing at least 2 L tumescent solution in a 70-kg 
adult.
Adverse Events with Tumescent Anesthesia
All reported adverse events associated with TLA have 
been the result of clinician error, such as inadvertent 
IV delivery of tumescent solution,57 miscommunication 
leading to excessive lidocaine in the tumescent lido-
caine solution, unawareness of drug interactions that 
reduce lidocaine metabolism by impairing cytochrome 
P450 1A2 and 3A4,58 and ad libitum formulations of 
tumescent solutions using bupivacaine, mepivacaine, or 
triamcinolone59 (Fig. 5).
In 1999, an influential report of 4 liposuction fatali-
ties concluded that, “Tumescent liposuction can be fatal; 
perhaps in part because of lidocaine toxicity or lidocaine-
related drug interactions.”60 All 4 patients received general 
anesthesia or heavy IV sedation. The tumescent lidocaine 
dosages were 10, 14.3, 31.4, and 40 mg/kg. Our data suggest 
that it was unlikely that tumescent lidocaine caused toxicity 
in these cases.
Study Limitations
Our estimates are preliminary and based on a sample of 
only 14 subjects. A larger sample size would provide both 
more evidence of the validity of our normality assump-
tions and more reliable tolerance interval estimates. Further 
proof of safety requires a randomized clinical trial involving 
patients with a wide range of clinical problems. Therapeutic 
surgeries without liposuction are likely to involve patients 
who are less healthy and who take more medications than 
do healthy liposuction patients. Unrecognized comorbidi-
ties and unanticipated clinical situations may be encoun-
tered. A patient may be taking a drug that impairs lidocaine 
metabolism and increases the risk of lidocaine toxicity. 
Pediatric patients, geriatric patients with impaired cardiac 
function, and patients with low or very high body mass 
index might not have the same pharmacokinetic response 
to tumescent lidocaine as a healthy adult. Any clinical con-
dition associated with slower lidocaine metabolism or faster 
lidocaine absorption requires a reduced lidocaine milligram 
per kilogram dosage.
The choice of a recommended maximum safe milligram 
per kilogram dosage should be tempered by the realiza-
tion that all statistical estimates are affected by sampling 
error. Careful clinical judgment must influence the choice 
of maximum permissible dosage for an individual patient.
Dilute tumescent lidocaine is safer than undiluted com-
mercial (0.5%, 1%, and 2%) solutions. When using undiluted 
commercial lidocaine with epinephrine, the traditional 
7 mg/kg dosage limit should be observed.
We performed subcutaneous infiltration of TLA using a 
specific technique and specially designed infiltration cannu-
las. Different techniques and different clinicians may have 
different results.
CONCLUSIONS
Within our sample of 14 subjects there was no evidence of 
lidocaine or epinephrine toxicity. Preliminary estimates for 
maximum safe dosages of tumescent lidocaine are 28 mg/kg 
without liposuction and 45mg/kg with liposuction. As a 
result of delayed systemic absorption, these dosages yield 
serum lidocaine concentrations below levels associated 
Table 3.  Risk of Lidocaine Serum Concentration >6 μg/mL (99% Confidence)
Dosage of tumescent lidocaine (mg/kg)
21 28 35 40 45 50 55
No liposuction < 1/1016 1/5 × 106 1/10,000 1/750 1/80 1/15 1/4
With liposuction 1/5 × 1010 1/2 × 107 1/2 × 105 1/15,000 1/2000 1/500 1/100
Estimated probabilities that any given dosage milligram per kilogram dosage will result in a peak serum lidocaine concentration (Cmax) ≥6 μg/mL, the threshold 
for mild lidocaine toxicity, were derived from tolerance interval analysis with a 99% level of confidence.
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with mild toxicity and represent a nonsignificant risk of 
harm to patients. E
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